Peter Marks received his graduate degree in cell and molecular biology and his medical degree at New York University and completed Internal Medicine residency and Hematology/Medical Oncology training at Brigham and Women’s Hospital in Boston. He has worked in academic settings teaching and caring for patients and in industry on drug development. In 2012, he joined the Food and Drug Administration and served as Director of the Center for Biologics Evaluation and Research from 2016 to 2025. During that time, he was integrally involved in the response to several public health emergencies and was elected to the National Academy of Medicine in 2022. He has published extensively and is a member of multiple professional societies. He is currently working as an independent consultant.